OSI Pharmaceuticals Initiates Clinical Development Program For Anti-Obesity Candidate, PSN602

 21.06.2008 06:14   medicalnewstoday.com

OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced that it has initiated the first-in-human clinical study of its development compound PSN602. Discovered by OSI's diabetes and obesity team, PSN602 is an oral dual serotonin and norepinephrine reuptake inhibitor and 5-HT1A agonist, being developed for the treatment of obesity. PSN602 is the first clinical candidate to emerge from the Company's research efforts in obesity.

World Weight Correction